Non-progressive placental abruption in incomplete pregnancy: aspects of diagnostic-therapeutic tactics

Authors

  • В. І. Пирогова Lviv National Medical University named after Danilo Galickyi, Ukraine
  • З. В. Сміх Lviv Regional Clinical Perinatal Centre, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2014.20.56-60

Keywords:

pregnancy, placental abruption, hemostasis, tranexamic acid

Abstract

Questions of accompany pregnancy with non-progressive partial placental abruption in incomplete pregnancy remain relevant for a long time and concern, in particular, the safety and efficacy of the use of hemostatic agents.
A study involving 127 patients with placental insufficiency, who were hospitalized at 22–26 weeks of gestation with signs of placental abruption was performed.
Patients were randomized into two groups: 32 pregnant of main group received tranexamic acid (drug Tranexam) as a hemostatic therapy, 15 patients of comparison group received etamsylatum.
As a result, it was found that the drug Tranexam in average daily doses (750–1 000 mg/day) for treatment duration of 5–7 days has more pronounced hemostatic effect, does not cause side effects, thus successfully maintain the pregnancy

Author Biographies

В. І. Пирогова, Lviv National Medical University named after Danilo Galickyi

MD, Professor, Head of Department of Obstetrics, Gynecology and Perinatology, Faculty of Continuing Education

З. В. Сміх, Lviv Regional Clinical Perinatal Centre

Doctor

References

Bilyk, N.M. “Pregnancy in women with risk of premature detachment of the placenta at prophylactic treatment.” Women’s Health, 1(2007):94-96.

Demina, T.N., Chaika, K.V. “Determination of D-dimer to predict thrombotic complications in pregnant and postpartum women at risk group.” Medical and Social Problems of the Family, 11(4) (2006):24-32.

Serov, V.N., Sukhikh, G.T. “Clinical recommendations. Obstetrics and gynecology.” M: GEOTAR -Media (2014):488-497.

Murashko, A.V., Kravchenko, N.F., Gribanova, N.D. “Hemorheological disorders in hypertension during pregnancy and their possible correction.” Gynecology, 9(5) (2007):17-19.

Sidelnikova, V.M., Kiryushchenkov, P.A.

Haemostasis and pregnancy. M.: Triada-X (2004).

Tingborn, L. “Inhibitors of fibrinolysis in the treatment of hemorrhagic disorders.” Hemophilia Treatment, 42 (2007).

Shevchenko, Y.L., et al. “Effect of blood saving of tranexamic acid.” Farmateka, 16(2008):17-25.

De Lange, N.M., Lancé, M.D., de Groot, R., et al. “Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage.” Obstet. Gynecol. Surv., 67(7) (2012):426-435.

Peitsidis, P., Kadir, R.A. “Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.” Expert Opin. Pharmacother, 12(4) (2011):503-516.

Rasmussen, S., Irgens, L.M. “Occurrence of placental abruption in relatives.” BJOG, 116(5) (2009):693.

Su, L.L., Chong, Y.S. “Massive obstetric haemorrhage with disseminated intravascular coagulopathy.” Best Pract. Res. Clin. Obstet. Gynaecol, 26(1) (2012):77-90.

Tower, C.L., Regan, L. “Intrauterine haematomas in a recurrent miscarriage population.” Hum. Reprod, 16(9) (2001):2005-2007.

Van Oppenraaij, R.H., Jauniaux, E., Christiansen, O.B., et al. “Predicting adverse obstetric outcome after early pregnancy events and complications: a review.” Hum. Reprod. Update, 15(4) (2009):409-421.

Published

2014-12-19

Issue

Section

Pregnancy and childbirth

Most read articles by the same author(s)